Journal: Nature biotechnology

Article Title: Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein.

doi: 10.1038/s41587-025-02648-2

Figure Lengend Snippet: Fig. 2 | Commercial and new anti-NPM1 antibodies detect csNPM1 across many human and murine AML models. a, Histograms of live cell flow cytometry of nine human leukemia cell lines stained with an isotype (gray) or the commercially available anti-NPM1 FC8791 (orange) antibody. AF, Alexa Fluor. b, Histograms of flow cytometry of four primary murine leukemias isolated from BM-derived cells. AML-driving mutations are noted; all models are on a Flt3ITD/+ background. The top row shows flow cytometry on the surface, and the bottom shows intracellular staining of cells that were first fixed and permeabilized before adding the anti-NPM1 (B0556) or isotype antibodies. c, Histograms of live cell flow cytometry on K562 cells that were transduced with an over expression plasmid containing no complementary DNA (cDNA) (empty vector) or cDNAs encoding Ty1-tagged NPM1-WT (Ty1-NPM1-WT) or the NPM1c mutant (Ty1- NPM1c). Cells were stained either with anti-NPM1 (B0556, left) or anti-Ty1 (right) antibodies. d, Contour plot of OCI-AML3 cell live staining with the mAb2 (red) or

Article Snippet: Input and enriched proteins were analyzed by Western blot, staining with anti-NPM1 antibody (Santa Cruz Biotechnology, sc-32256, FC8791) and streptavidin IR800 (LI-COR Biotechnology) and finally scanning on a LI-COR Odyssey CLx scanner.

Techniques: Flow Cytometry, Staining, Isolation, Derivative Assay, Transduction, Over Expression, Plasmid Preparation, Mutagenesis